Search

everythinglearnresearchcommunity

for

Search:↓

Farudodstat can prevent hair follicle immune damage linked to alopecia areata.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

NK cells play a role in skin diseases like eczema and psoriasis.

JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

Adalimumab helped control a child's severe eye disease when other treatments failed.

TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Nanomedicine-based immunotherapy shows promise in improving tissue repair and regeneration.

Immunosuppression therapy with methylprednisolone effectively treats childhood alopecia areata.

Transplant success has improved with better immunosuppressive drugs and donor matching.

TNF-inhibitor induced alopecia can be treated effectively with different therapies.

Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.

Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.

Combination therapies might work better for some vitiligo patients, but results vary.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.